1. ALLA AKTIER
  2. NYHETER
  3. DEVYSER DIAGNOSTICS

Devyser Diagnostics

Nyheter Devyser Diagnostics Nyheter alla bolag

Devyser to share data at ASHI 2024 demonstrating its innovations and studies within transplantation

Devyser’s post-transplant products will be featured in 7 posters at the upcoming American Society of Histocompatibility and Immunogenetics (ASHI) meeting at Anaheim California in October, highlighting advancements in donor-derived cell-free DNA (dd-cfDNA) monitoring and innovations. These presentations include performance assessments of novel assays and advancements in monitoring tools for kidney and lung transplants. We will present a new prototype product for the absolute quantification of dd-cfDNA using next-generation sequencing (NGS). The research underscores Devyser's commitment to driving innovation in transplantation diagnostics and improving patient care.

"Devyser is a pioneering leader within the field of transplant diagnostics. We are committed to advancing the field together with our collaborators and partners, and we are now showcasing some of our latest studies and inventions at the upcoming ASHI meeting in the USA", says CSO Michael Uhlin. "We look forward to sharing and discussing with the transplant community how our tests can contribute towards improved outcomes in post-transplant monitoring."

Complete list of Devyser and collaborator presentations at ASHI 2024

AbstractTitle (Platinum Ballroom unless otherwise specified)Product
P605Performance Assessment of the One Lamba Devyser Accept cfDNA assay in lung transplantationOne Lambda Devyser Accept cfDNA
P613Pooling HLA, chimerism, and cfDNA NGS libraries for sequencing on Illumina instrumentsOne Lambda Devyser Accept cfDNA
One Lambda Devyser Chimerism
P703Advancing transplantation monitoring and disease insightIn development
P704Absolute quantification of dd-cfDNA using a novel NGS assayIn development
P714Evaluation of cfDNA extraction methodOne Lambda Devyser Accept cfDNA
P716Advancements in monitoring donor-derived cell-free DNA for improved kidney re-transplantation outcomesOne Lambda Devyser Accept cfDNA
Session Abstract VComparing the performance of Devyser and CareDx NGS based-assays for monitoring donor-derived cell-free DNA in kidney allografted patientsOne Lambda Devyser Accept cfDNA

The One Lambda™ Devyser Accept cfDNA test, is for detecting donor-derived cell-free DNA in kidney transplant patients. Advyser Solid Organs is our dedicated software solutions for streamlined, user-friendly, and fast monitoring of donor-derived cell-free DNA (dd-cfDNA) in patients following kidney transplantation.

The One Lambda Devyser transplantation products are CE-IVD certified but not FDA-cleared. Availability in each country depends on local regulatory marketing authorization status. Please consult your local sales representative for details. 

For more information, please contact:
Fredrik Alpsten, CEO
Email: fredrik.alpsten@devyser.com
Telephone: +46 70 667 31 06

Michael Uhlin, CSO
Email: michael.uhlin@devyser.com
Telephone: +46 70 092 23 24

About Devyser
Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.

Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.

Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB. 

For more information, visit www.devyser.com. 

Attachments
Devyser to share data at ASHI 2024 demonstrating its innovations and studies within transplantation

Datum 2024-09-24, kl 08:00
Källa MFN
Bifogade filer
Devyser to share data at ASHI 2024 demonstrating its innovations and studies within transplantation
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!